inositol has been researched along with Amentia in 25 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The mean CSF concentration and the mean CSF/plasma concentration ratio of myo-inositol were significantly elevated in Down syndrome compared with controls, but were not correlated with the presence of dementia in the Down subjects." | 9.08 | Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid. ( Holloway, HW; Rapoport, SI; Schapiro, MB; Shetty, HU, 1995) |
| "The aim of study was to search for new biomarkers with a magnetic resonance technique to identify the early stages of dementia, induced by D-galactose, and evaluate Simvastatin therapy." | 7.81 | Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study. ( Dubovický, M; Kašparová, S; Kucharská, J; Liptaj, T; Lipták, B; Sumbalová, Z; Szomolányi, P; Trattnig, S; Tušková, R; Uličná, O; Vančová, O, 2015) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 7.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| " The mean CSF concentration and the mean CSF/plasma concentration ratio of myo-inositol were significantly elevated in Down syndrome compared with controls, but were not correlated with the presence of dementia in the Down subjects." | 5.08 | Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid. ( Holloway, HW; Rapoport, SI; Schapiro, MB; Shetty, HU, 1995) |
| "Neurodegenerative dementias are characterized by elevated myoinositol and decreased N-acetylaspartate (NAA) levels." | 4.89 | Magnetic resonance spectroscopy in common dementias. ( Kantarci, K, 2013) |
| "The aim of study was to search for new biomarkers with a magnetic resonance technique to identify the early stages of dementia, induced by D-galactose, and evaluate Simvastatin therapy." | 3.81 | Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study. ( Dubovický, M; Kašparová, S; Kucharská, J; Liptaj, T; Lipták, B; Sumbalová, Z; Szomolányi, P; Trattnig, S; Tušková, R; Uličná, O; Vančová, O, 2015) |
| " Myo-inositol (mI), whose transporter gene is located on chromosome 21, has been associated with dementia in the non-DS population; however, nobody has contrasted brain mI in DS with (DS+) and without (DS-) dementia to other non-DS groups." | 3.77 | Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. ( Archer, N; Beacher, F; Daly, E; Foy, CML; Lamar, M; Lovestone, S; Morris, RG; Murphy, DGM; Murphy, KC; Poppe, M; Prasher, V; Simmons, A, 2011) |
| " Although changes in myo-inositol and creatine occur in the early stages of AD, abnormalities of N-acetyl aspartate do not occur in mild AD but progressively change with dementia severity." | 3.71 | Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. ( Alexander, GE; Chang, L; Huang, W; Krasuski, JS; Rapoport, SI; Schapiro, MB; Shetty, HU, 2001) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 3.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "To evaluate cerebral biochemical abnormalities in patients with frontotemporal dementia and Alzheimer disease and to determine whether proton (hydrogen-1) magnetic resonance (MR) spectroscopy can help differentiate among these two patient groups and healthy (control) subjects." | 3.69 | Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. ( Chang, L; Ernst, T; Mehringer, CM; Melchor, R, 1997) |
| "Dementia was an independent predictor of metabolite values." | 2.73 | Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. ( Antúnez, C; Carles, R; Fortuna, L; García Santos, JM; Gavrila, D; Jiménez Veiga, J; Navarro, C; Parrilla, G; Salmerón, D; Tormo, MJ; Torres del Río, S, 2008) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moccia, F | 1 |
| Negri, S | 1 |
| Faris, P | 1 |
| Angelone, T | 1 |
| Kantarci, K | 3 |
| Targosz-Gajniak, MG | 1 |
| Siuda, JS | 1 |
| Wicher, MM | 1 |
| Banasik, TJ | 1 |
| Bujak, MA | 1 |
| Augusciak-Duma, AM | 1 |
| Opala, G | 1 |
| Tušková, R | 1 |
| Lipták, B | 1 |
| Szomolányi, P | 1 |
| Vančová, O | 1 |
| Uličná, O | 1 |
| Sumbalová, Z | 1 |
| Kucharská, J | 1 |
| Dubovický, M | 1 |
| Trattnig, S | 1 |
| Liptaj, T | 1 |
| Kašparová, S | 1 |
| Almuqbel, M | 1 |
| Melzer, TR | 1 |
| Myall, DJ | 1 |
| MacAskill, MR | 1 |
| Pitcher, TL | 1 |
| Livingston, L | 1 |
| Wood, KL | 1 |
| Keenan, RJ | 1 |
| Dalrymple-Alford, JC | 1 |
| Anderson, TJ | 1 |
| Lin, AL | 1 |
| Powell, D | 1 |
| Caban-Holt, A | 1 |
| Jicha, G | 1 |
| Robertson, W | 1 |
| Gold, BT | 1 |
| Davis, R | 1 |
| Abner, E | 1 |
| Wilcock, DM | 1 |
| Schmitt, FA | 1 |
| Head, E | 1 |
| García Santos, JM | 1 |
| Gavrila, D | 1 |
| Antúnez, C | 1 |
| Tormo, MJ | 1 |
| Salmerón, D | 1 |
| Carles, R | 1 |
| Jiménez Veiga, J | 1 |
| Parrilla, G | 1 |
| Torres del Río, S | 1 |
| Fortuna, L | 1 |
| Navarro, C | 1 |
| Caserta, MT | 1 |
| Ragin, A | 1 |
| Hermida, AP | 1 |
| Ahrens, RJ | 1 |
| Wise, L | 1 |
| Pilatus, U | 1 |
| Lais, C | 1 |
| Rochmont, Adu M | 1 |
| Kratzsch, T | 1 |
| Frölich, L | 1 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Lanfermann, H | 1 |
| Pantel, J | 1 |
| Lamar, M | 1 |
| Foy, CML | 1 |
| Beacher, F | 1 |
| Daly, E | 1 |
| Poppe, M | 1 |
| Archer, N | 1 |
| Prasher, V | 1 |
| Murphy, KC | 1 |
| Morris, RG | 1 |
| Simmons, A | 1 |
| Lovestone, S | 1 |
| Murphy, DGM | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| VIDAL-TEIXIDOR, R | 1 |
| GARCIA-BUNUEL, L | 1 |
| GARCIA-BUNUEL, M | 1 |
| Petersen, RC | 1 |
| Boeve, BF | 1 |
| Knopman, DS | 1 |
| Tang-Wai, DF | 1 |
| O'Brien, PC | 1 |
| Weigand, SD | 1 |
| Edland, SD | 1 |
| Smith, GE | 1 |
| Ivnik, RJ | 1 |
| Ferman, TJ | 1 |
| Tangalos, EG | 1 |
| Jack, CR | 1 |
| Frederick, BD | 1 |
| Lyoo, IK | 1 |
| Satlin, A | 1 |
| Ahn, KH | 1 |
| Kim, MJ | 1 |
| Yurgelun-Todd, DA | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Metastasio, A | 1 |
| Rinaldi, P | 1 |
| Tarducci, R | 1 |
| Mariani, E | 1 |
| Feliziani, FT | 1 |
| Cherubini, A | 1 |
| Pelliccioli, GP | 1 |
| Gobbi, G | 1 |
| Senin, U | 1 |
| Mecocci, P | 1 |
| Coulthard, E | 1 |
| Firbank, M | 1 |
| English, P | 1 |
| Welch, J | 1 |
| Birchall, D | 1 |
| O'Brien, J | 1 |
| Griffiths, TD | 1 |
| Garrard, P | 1 |
| Schott, JM | 1 |
| MacManus, DG | 1 |
| Hodges, JR | 1 |
| Fox, NC | 1 |
| Waldman, AD | 1 |
| Shonk, T | 1 |
| Ross, BD | 2 |
| Shetty, HU | 2 |
| Schapiro, MB | 2 |
| Holloway, HW | 1 |
| Rapoport, SI | 2 |
| Shonk, TK | 1 |
| Moats, RA | 1 |
| Gifford, P | 1 |
| Michaelis, T | 1 |
| Mandigo, JC | 1 |
| Izumi, J | 1 |
| Ernst, T | 1 |
| Chang, L | 2 |
| Melchor, R | 1 |
| Mehringer, CM | 1 |
| Huang, W | 1 |
| Alexander, GE | 1 |
| Krasuski, JS | 1 |
| Lourander, L | 1 |
| Ruikka, I | 1 |
| Rautakorpi, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT02921477] | Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | ||
| Focused Ultrasound Delivery of Exosomes for Treatment of Refractory Depression, Anxiety, and Neurodegenerative Dementias[NCT04202770] | 300 participants (Anticipated) | Interventional | 2019-12-01 | Suspended (stopped due to Pending COVID-19 pandemic; pending status of product development) | |||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
2 reviews available for inositol and Amentia
| Article | Year |
|---|---|
Proton MRS in mild cognitive impairment.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Cognitive Dysfunction; Creati | 2013 |
Magnetic resonance spectroscopy in common dementias.
Topics: Aspartic Acid; Biomarkers; Brain; Dementia; Humans; Inositol; Magnetic Resonance Spectroscopy | 2013 |
4 trials available for inositol and Amentia
| Article | Year |
|---|---|
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2008 |
Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.
Topics: Adult; Age Factors; Aged; Biomarkers; Dementia; Down Syndrome; Female; Gas Chromatography-Mass Spect | 1995 |
Probable Alzheimer disease: diagnosis with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases, Metabolic; Creatine; Dementia; Diagno | 1995 |
Psychological methods applied to evaluate symptomatic geriatric treatment.
Topics: Aged; Clinical Trials as Topic; Dementia; Ethanol; Female; Geriatrics; Humans; Inositol; Kinesthesis | 1970 |
19 other studies available for inositol and Amentia
| Article | Year |
|---|---|
Targeting endothelial ion signalling to rescue cerebral blood flow in cerebral disorders.
Topics: Ankyrins; Cerebrovascular Circulation; Dementia; Endothelial Cells; Endothelium, Vascular; Humans; I | 2022 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study.
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Dementia; Dipeptides; Disease Models, Animal; Galactose; | 2015 |
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Bayes Theorem; Case-Control Studies; Choline; Cognitive Dysf | 2016 |
(1)H-MRS metabolites in adults with Down syndrome: Effects of dementia.
Topics: Activities of Daily Living; Adult; Analysis of Variance; Aspartic Acid; Dementia; Down Syndrome; Fem | 2016 |
Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: early right hippocampal NAA/Cr loss in mildly impaired subjects.
Topics: Aged; Aspartic Acid; Choline; Creatine; Dementia; Female; Functional Laterality; Hippocampus; Humans | 2008 |
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De | 2009 |
Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Case-Control Studies; Dementia; Down Syndro | 2011 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
[On the treatment of depressive states in aged persons].
Topics: Dementia; Depression; Depressive Disorder; Humans; Inositol; Pentylenetetrazole; Psychotic Disorders | 1963 |
CEREBROSPINAL FLUID LEVELS OF FREE MYOINOSITOL IN SOME NEUROLOGICAL DISORDERS.
Topics: Biochemical Phenomena; Biochemistry; Cerebrospinal Fluid; Child; Dementia; Diabetic Neuropathies; Ge | 1965 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy.
Topics: Aged; Amnesia; Aspartic Acid; Cerebral Cortex; Choline; Cognition Disorders; Creatine; Dementia; Dis | 2006 |
Proton magnetic resonance spectroscopy in frontotemporal dementia.
Topics: Aged; Aspartic Acid; Biomarkers; Cerebral Cortex; Dementia; Female; Frontal Lobe; Gliosis; Gyrus Cin | 2006 |
Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Atrophy; Dementia; Diagnosis, Differential; Female; Frontal | 2006 |
Role of increased cerebral myo-inositol in the dementia of Down syndrome.
Topics: Adolescent; Adult; Alzheimer Disease; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creati | 1995 |
Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Dementia; Discriminant Analysis; Female; | 1997 |
Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Choline; Cre | 2001 |